GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alterity Therapeutics ATHE · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.43

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Alterity Therapeutics

Its shares trade under the ticker ATHE. It has been listed since 5 September 2002. In the fiscal year to 30 June 2025, it reported revenue of $3.9m and a net loss of $8.6m. At that date it held total assets of $32.8m and shareholders' equity of $30.2m.

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
5 Sept 2002
Employees
9
Head office
LEVEL 15, 500 COLLINS STREET, MELBOURNE, VIC 3000
Incorporated in
C3
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • ATH434 completed Phase II clinical trial for Parkinson's disease treatment.
  • ATH434-201 and ATH434-202 are in Phase II trials for MSA treatment.
  • Alterity Therapeutics operates a drug discovery platform for neurological diseases.

Weaknesses

  • The company has only 9 employees.
  • Alterity Therapeutics is based in Melbourne, Australia.
  • The company was formerly Prana Biotechnology Limited.

Opportunities

  • The company's lead drug candidate ATH434 has completed Phase II trials.
  • ATH434-201 and ATH434-202 are in Phase II trials for MSA.
  • Alterity Therapeutics' drug discovery platform can generate patentable compounds.

Threats

  • The company has only 9 employees.
  • Alterity Therapeutics is based in Melbourne, Australia.
  • The company was formerly Prana Biotechnology Limited.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.